October 15, 2018 / 5:49 AM / a month ago

BRIEF-Roche Says Satralizumab Added To Baseline Therapy Reduced Risk Of Relapse

Oct 15 (Reuters) - Roche Holding AG:

* CHUGAI PRESENTS RESULTS FROM PHASE III STUDY OF SATRALIZUMAB IN NMOSD AT ECTRIMS 2018

* SATRALIZUMAB ADDED TO BASELINE THERAPY SIGNIFICANTLY REDUCED RISK OF RELAPSE

* RESULTS WERE PRESENTED AT ECTRIMS CONGRESS HELD IN BERLIN FROM OCTOBER 10 TO 12 Source text for Eikon: [bit.ly/2EmibNS] Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below